These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 19176385)
1. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Beevers CS; Chen L; Liu L; Luo Y; Webster NJ; Huang S Cancer Res; 2009 Feb; 69(3):1000-8. PubMed ID: 19176385 [TBL] [Abstract][Full Text] [Related]
2. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756 [TBL] [Abstract][Full Text] [Related]
3. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Beevers CS; Li F; Liu L; Huang S Int J Cancer; 2006 Aug; 119(4):757-64. PubMed ID: 16550606 [TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Johnson SM; Gulhati P; Arrieta I; Wang X; Uchida T; Gao T; Evers BM Anticancer Res; 2009 Aug; 29(8):3185-90. PubMed ID: 19661333 [TBL] [Abstract][Full Text] [Related]
5. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells. Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235 [TBL] [Abstract][Full Text] [Related]
7. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. Oshiro N; Takahashi R; Yoshino K; Tanimura K; Nakashima A; Eguchi S; Miyamoto T; Hara K; Takehana K; Avruch J; Kikkawa U; Yonezawa K J Biol Chem; 2007 Jul; 282(28):20329-39. PubMed ID: 17517883 [TBL] [Abstract][Full Text] [Related]
8. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Chen L; Xu B; Liu L; Luo Y; Yin J; Zhou H; Chen W; Shen T; Han X; Huang S Lab Invest; 2010 May; 90(5):762-73. PubMed ID: 20142804 [TBL] [Abstract][Full Text] [Related]
9. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421 [TBL] [Abstract][Full Text] [Related]
10. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. Fonseca BD; Smith EM; Lee VH; MacKintosh C; Proud CG J Biol Chem; 2007 Aug; 282(34):24514-24. PubMed ID: 17604271 [TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141 [TBL] [Abstract][Full Text] [Related]
13. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells. Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838 [TBL] [Abstract][Full Text] [Related]
14. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. Wang L; Harris TE; Roth RA; Lawrence JC J Biol Chem; 2007 Jul; 282(27):20036-44. PubMed ID: 17510057 [TBL] [Abstract][Full Text] [Related]
15. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574 [TBL] [Abstract][Full Text] [Related]
16. Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction. Hong-Brown LQ; Brown CR; Kazi AA; Huber DS; Pruznak AM; Lang CH J Cell Biochem; 2010 Apr; 109(6):1172-84. PubMed ID: 20127721 [TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815 [TBL] [Abstract][Full Text] [Related]
18. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. Agarwal S; Bell CM; Rothbart SB; Moran RG J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395 [TBL] [Abstract][Full Text] [Related]
19. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Shaw RJ Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654 [TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]